Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity
Executive Summary
Hemlibra was approved to prevent or reduce bleeding in adults and children with hemophilia A without factor VIII inhibitors, a significantly larger patient population than its current indication in patients with factor VIII inhibitors.
You may also be interested in...
Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
Dupixent And Vaccines Dominate As Sanofi Profits Rise
Sales of Praluent and Eloctate disappointed but the promise of further growth for big-selling Dupixent augurs well for the French firm's future.